Baseline Demographics and Comorbidities in Patients With Atopic Dermatitis: an Update From the GLOBOSTAD Registry
Abstrakt
The efficary and safety of dupilumab have been reported previously based on data from controlled clinical trials. The GLOBOSTAD study extends the scope of these trials by providing real-world data. this analysis reports baseline demographics and family disease history in patients with atopic dermatitis (AD) who received treatment with dupilumab in real-world setting.